Anti-Müllerian hormone: An ovarian reserve marker in primary ovarian insufficiency

Nature Reviews Endocrinology

Volumn 8, Issue 6, 2012, Pages 331-341

  Visser, Jenny A ^a   Schipper, Izaäk ^b   Laven, Joop S E ^b   Themmen, Axel P N ^a  

^a Ee532 ^*  (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; CHLORMETHINE; CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; EPIRUBICIN; GONADORELIN DERIVATIVE; MARKER; MUELLERIAN INHIBITING FACTOR; PREDNISONE; PROCARBAZINE; VINBLASTINE; VINCRISTINE;

ADRENAL INSUFFICIENCY; AUTOIMMUNITY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CANCER THERAPY; CHILDHOOD LEUKEMIA; COUNSELING; DISEASE MARKER; EARLY DIAGNOSIS; FEMALE INFERTILITY; GENETIC DISORDER; GONAD DYSFUNCTION; HODGKIN DISEASE; HORMONE BLOOD LEVEL; HUMAN; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; INFERTILITY THERAPY; MENOPAUSE; MOSAICISM; MULTIPLE CYCLE TREATMENT; NONHUMAN; OVARIAN RESERVE; OVARY FOLLICLE DEVELOPMENT; OVARY FOLLICLE MATURATION; OVARY INSUFFICIENCY; PREMATURE OVARIAN FAILURE; PRIORITY JOURNAL; REVIEW; SENESCENCE; TURNER SYNDROME;

ANTI-MULLERIAN HORMONE; BIOLOGICAL MARKERS; FEMALE; HUMANS; OVARIAN FOLLICLE; OVARY; PRIMARY OVARIAN INSUFFICIENCY;

EID: 84861330616     PISSN: 17595029     EISSN: 17595037     Source Type: Journal    
DOI: 10.1038/nrendo.2011.224     Document Type: Review

References (147)

1. Conway, G. S. Premature ovarian failure. Br. Med. Bull. 56, 643-649 (2000). (Pubitemid 32041658)
2. Albright, F., Smith, P. H. & Fraser, R. A syndrome characterized by primary ovarian insufficiency and decreased stature: Report of 11 cases with a digression on hormonal control of axillary and pubic hair. Am. J. Med. Sci. 204, 625-648 (1942).
3. Welt, C. K. Primary ovarian insufficiency: a more accurate term for premature ovarian failure. Clin. Endocrinol. (Oxf.) 68, 499-509 (2008). (Pubitemid 351388699)
4. Nelson, L. M. Clinical practice. Primary ovarian insufficiency. N. Engl. J. Med. 360, 606-614 (2009).
5. De Vos, M., Devroey, P. & Fauser, B. C. Primary ovarian insufficiency. Lancet 376, 911-921 (2010).
6. te Velde, E. R. & Pearson, P. L. The variability of female reproductive ageing. Hum. Reprod. Update 8, 141-154 (2002). (Pubitemid 34428965)
7. Coulam, C. B., Adamson, S. C. & Annegers, J. F. Incidence of premature ovarian failure. Obstet. Gynecol. 67, 604-606 (1986). (Pubitemid 16116286)
8. Anasti, J. N. Premature ovarian failure: an update. Fertil. Steril. 70, 1-15 (1998). (Pubitemid 28294613)
9. Persani, L., Rossetti, R. & Cacciatore, C. Genes involved in human premature ovarian failure. J. Mol. Endocrinol. 45, 257-279 (2010).
10. Matzuk, M. M. & Lamb, D. J. The biology of infertility: research advances and clinical challenges. Nat. Med. 14, 1197-1213 (2008).
11. Bakalov, V. K. et al. Autoimmune oophoritis as a mechanism of follicular dysfunction in women with 46,XX spontaneous premature ovarian failure. Fertil. Steril. 84, 958-965 (2005). (Pubitemid 41414587)
12. Aittomäki, K. et al. Mutation in the follicle-stimulating hormone receptor gene causes hereditary hypergonadotropic ovarian failure. Cell 82, 959-968 (1995).
13. Latronico, A. C. et al. Brief report: testicular and ovarian resistance to luteinizing hormone caused by inactivating mutations of the luteinizing hormone-receptor gene. N. Engl. J. Med. 334, 507-512 (1996). (Pubitemid 26067739)
14. Araki, S. et al. Arrest of follicular development in a patient with 17 alpha-hydroxylase deficiency: folliculogenesis in association with a lack of estrogen synthesis in the ovaries. Fertil. Steril. 47, 169-172 (1987). (Pubitemid 17004183)
15. Conte, F. A., Grumbach, M. M., Ito, Y., Fisher, C. R. & Simpson, E. R. A syndrome of female pseudohermaphrodism, hypergonadotropic hypogonadism, and multicystic ovaries associated with missense mutations in the gene encoding aromatase (P450arom). J. Clin. Endocrinol. Metab. 78, 1287-1292 (1994). (Pubitemid 24180993)
16. Nelson, L. M. et al. Development of luteinized graafian follicles in patients with karyotypically normal spontaneous premature ovarian failure. J. Clin. Endocrinol. Metab. 79, 1470-1475 (1994). (Pubitemid 24369868)
17. Nelson, L. M., Covington, S. N. & Rebar, R. W. An update: spontaneous premature ovarian failure is not an early menopause. Fertil. Steril. 83, 1327-1332 (2005). (Pubitemid 40615800)
18. Hubayter, Z. R. et al. A prospective evaluation of antral follicle function in women with 46, XX spontaneous primary ovarian insufficiency. Fertil. Steril. 94, 1769-1774 (2010).
19. Karimov, C. B. et al. Increased frequency of occult fragile X-associated primary ovarian insufficiency in infertile women with evidence of impaired ovarian function. Hum. Reprod. 26, 2077-2083 (2011).
20. Goswami, D. & Conway, G. S. Premature ovarian failure. Hum. Reprod. Update 11, 391-410 (2005). (Pubitemid 40895467)
21. Skillern, A. & Rajkovic, A. Recent developments in identifying genetic determinants of premature ovarian failure. Sex. Dev. 2, 228-243 (2008).
22. Knauff, E. A. et al. Genome-wide association study in premature ovarian failure patients suggests ADAMTS19 as a possible candidate gene. Hum. Reprod. 24, 2372-2378 (2009).
23. van Dooren, M. F., Bertoli-Avellab, A. M. & Oldenburg, R. A. Premature ovarian failure and gene polymorphisms. Curr. Opin. Obstet. Gynecol. 21, 313-317 (2009).
24. Oldenburg, R. A. et al. A genome-wide linkage scan in a Dutch family identifies a premature ovarian failure susceptibility locus. Hum. Reprod. 23, 2835-2841 (2008).
25. Christin-Maitre, S. & Tachdjian, G. Genome-wide association study and premature ovarian failure. Ann. Endocrinol. (Paris) 71, 218-221 (2010).
26. Bondy, C. A. Care of girls and women with Turner syndrome: a guideline of the Turner Syndrome Study Group. J. Clin. Endocrinol. Metab. 92, 10-25 (2007). (Pubitemid 46067503)
27. Saenger, P. et al. Recommendations for the diagnosis and management of Turner syndrome. J. Clin. Endocrinol. Metab. 86, 3061-3069 (2001). (Pubitemid 32673466)
28. Sherman, S. L. Premature ovarian failure in the fragile X syndrome. Am. J. Med. Genet. 97, 189-194 (2000). (Pubitemid 32059206)
29. Verkerk, A. J. et al. Identification of a gene (FMR-1) containing a CGG repeat coincident with a breakpoint cluster region exhibiting length variation in fragile X syndrome. Cell 65, 905-914 (1991). (Pubitemid 121001321)
30. Fu, Y. H. et al. Variation of the CGG repeat at the fragile X site results in genetic instability: resolution of the Sherman paradox. Cell 67, 1047-1058 (1991).
31. Allingham-Hawkins, D. J. et al. Fragile X premutation is a significant risk factor for premature ovarian failure: the International Collaborative POF in Fragile X study-preliminary data. Am. J. Med. Genet. 83, 322-325 (1999). (Pubitemid 29162637)
32. Conway, G. S., Payne, N. N., Webb, J., Murray, A. & Jacobs, P. A. Fragile X premutation screening in women with premature ovarian failure. Hum. Reprod. 13, 1184-1187 (1998). (Pubitemid 28279167)
33. Conway, G. S., Kaltsas, G., Patel, A., Davies, M. C. & Jacobs, H. S. Characterization of idiopathic premature ovarian failure. Fertil. Steril. 65, 337-341 (1996). (Pubitemid 26043830)
34. Novosad, J. A., Kalantaridou, S. N., Tong, Z. B. & Nelson, L. M. Ovarian antibodies as detected by indirect immunofluorescence are unreliable in the diagnosis of autoimmune premature ovarian failure: a controlled evaluation. BMC Womens Health 3, 2 (2003).
35. La Marca, A. et al. Primary ovarian insufficiency: autoimmune causes. Curr. Opin. Obstet. Gynecol. 22, 277-282 (2010).
36. Gatta, G., Capocaccia, R., Coleman, M. P., Ries, L. A. & Berrino, F. Childhood cancer survival in Europe and the United States. Cancer 95, 1767-1772 (2002).
37. Gatta, G. et al. Childhood cancer survival trends in Europe: a EUROCARE Working Group study. J. Clin. Oncol. 23, 3742-3751 (2005).
38. Edgar, A. B., Morris, E. M., Kelnar, C. J. & Wallace, W. H. Long-term follow-up of survivors of childhood cancer. Endocr. Dev. 15, 159-180 (2009).
39. Bath, L. E., Wallace, W. H. & Critchley, H. O. Late effects of the treatment of childhood cancer on the female reproductive system and the potential for fertility preservation. BJOG 109, 107-114 (2002). (Pubitemid 37338030)
40. van Dorp, W. et al. Long-term endocrine side effects of childhood Hodgkin's lymphoma treatment: a review. Hum. Reprod. Update http://dx.doi.org/ 10.1093/humupd/dmr038.
41. Brougham, M. F. & Wallace, W. H. Subfertility in children and young people treated for solid and haematological malignancies. Br. J. Haematol. 131, 143-155 (2005). (Pubitemid 43899679)
42. Shelling, A. N. Premature ovarian failure. Reproduction 140, 633-641 (2010).
43. Josso, N. et al. Anti-müllerian hormone: the Jost factor. Recent Prog. Horm. Res. 48, 1-59 (1993).
44. Lee, M. M. & Donahoe, P. K. Müllerian inhibiting substance: a gonadal hormone with multiple functions. Endocr. Rev. 14, 152-164 (1993). (Pubitemid 23118414)
45. Josso, N., Picard, J. Y. & Tran, D. The anti-Müllerian hormone. Birth Defects Orig. Artic. Ser. 13, 59-84 (1977).
46. Durlinger, A. L., Visser, J. A. & Themmen, A. P. Regulation of ovarian function: the role of anti-Müllerian hormone. Reproduction 124, 601-609 (2002). (Pubitemid 35402334)
47. Rajpert-De Meyts, E. et al. Expression of anti-Müllerian hormone during normal and pathological gonadal development: association with differentiation of Sertoli and granulosa cells. J. Clin. Endocrinol. Metab. 84, 3836-3844 (1999). (Pubitemid 30645250)
48. Weenen, C. et al. Anti-Müllerian hormone expression pattern in the human ovary: potential implications for initial and cyclic follicle recruitment. Mol. Hum. Reprod. 10, 77-83 (2004). (Pubitemid 38196508)
49. Shi, J. et al. Bone morphogenetic protein-6 stimulates gene expression of follicle-stimulating hormone receptor, inhibin/activin beta subunits, and anti-Müllerian hormone in human granulosa cells. Fertil. Steril. 92, 1794-1798 (2009).
50. Salmon, N. A., Handyside, A. H. & Joyce, I. M. Oocyte regulation of anti-Müllerian hormone expression in granulosa cells during ovarian follicle development in mice. Dev. Biol. 266, 201-208 (2004). (Pubitemid 38083206)
51. Grøndahl, M. L. et al. Anti-Müllerian hormone remains highly expressed in human cumulus cells during the final stages of folliculogenesis. Reprod. Biomed. Online 22, 389-398 (2011).
52. McGee, E. A. & Hsueh, A. J. Initial and cyclic recruitment of ovarian follicles. Endocr. Rev. 21, 200-214 (2000). (Pubitemid 32275595)
53. Durlinger, A. L. L. et al. Control of primordial follicle recruitment by anti-Müllerian hormone in the mouse ovary. Endocrinology 140, 5789-5796 (1999). (Pubitemid 30645368)
54. Carlsson, I. B. et al. Anti-Müllerian hormone inhibits initiation of growth of human primordial ovarian follicles in vitro. Hum. Reprod. 21, 2223-2227 (2006). (Pubitemid 44530593)
55. Durlinger, A. L. L. et al. Anti-Müllerian hormone inhibits initiation of primordial follicle growth in the mouse ovary. Endocrinology 143, 1076-1084 (2002). (Pubitemid 34164056)
56. Gigli, I., Cushman, R. A., Wahl, C. M. & Fortune, J. E. Evidence for a role for anti-Müllerian hormone in the suppression of follicle activation in mouse ovaries and bovine ovarian cortex grafted beneath the chick chorioallantoic membrane. Mol. Reprod. Dev. 71, 480-488 (2005). (Pubitemid 40923515)
57. Kevenaar, M. E. et al. A polymorphism in the AMH type II receptor gene is associated with age at menopause in interaction with parity. Hum. Reprod. 22, 2382-2388 (2007). (Pubitemid 47289053)
58. Durlinger, A. L. L. et al. Anti-Müllerian hormone attenuates the effects of FSH on follicle development in the mouse ovary. Endocrinology 142, 4891-4899 (2001). (Pubitemid 33022365)
59. Visser, J. A. et al. Increased oocyte degeneration and follicular atresia during the estrous cycle in anti-Müllerian hormone null mice. Endocrinology 148, 2301-2308 (2007). (Pubitemid 46997082)
60. di Clemente, N. et al. Inhibitory effect of AMH upon the expression of aromatase and LH receptors of granulosa cells of rat and porcine immature ovaries. Endocrine 2, 553-558 (1994).
61. Grossman, M. P., Nakajima, S. T., Fallat, M. E. & Siow, Y. Müllerian-inhibiting substance inhibits cytochrome P450 aromatase activity in human granulosa lutein cell culture. Fertil. Steril. 89, 1364-1370 (2008). (Pubitemid 351680087)
62. Andersen, C. Y. & Byskov, A. G. Estradiol and regulation of anti-Müllerian hormone, inhibin-A, and inhibin-B secretion: analysis of small antral and preovulatory human follicles' fluid. J. Clin. Endocrinol. Metab. 91, 4064-4069 (2006). (Pubitemid 44536886)
63. Kevenaar, M. E. et al. Anti-Müllerian hormone and anti-Müllerian hormone type II receptor polymorphisms are associated with follicular phase estradiol levels in normo-ovulatory women. Hum. Reprod. 22, 1547-1554 (2007). (Pubitemid 47055141)
64. te Velde, E. R., Scheffer, G. J., Dorland, M., Broekmans, F. J. & Fauser, B. C. Developmental and endocrine aspects of normal ovarian aging. Mol. Cell. Endocrinol. 145, 67-73 (1998). (Pubitemid 29003179)
65. Scheffer, G. J. et al. Antral follicle counts by transvaginal ultrasonography are related to age in women with proven natural fertility. Fertil. Steril. 72, 845-851 (1999). (Pubitemid 29505448)
66. Bergada, I. et al. Time course of the serum gonadotropin surge, inhibins, and anti-Müllerian hormone in normal newborn males during the first month of life. J. Clin. Endocrinol. Metab. 91, 4092-4098 (2006). (Pubitemid 44536890)
67. Guibourdenche, J. et al. Anti-Müllerian hormone levels in serum from human foetuses and children: pattern and clinical interest. Mol. Cell. Endocrinol. 211, 55-63 (2003). (Pubitemid 37491236)
68. Hagen, C. P. et al. Serum levels of anti-Müllerian hormone as a marker of ovarian function in 926 healthy females from birth to adulthood and in 172 Turner syndrome patients. J. Clin. Endocrinol. Metab. 95, 5003-5010 (2010).
69. Lee, M. M. et al. Mullerian inhibiting substance in humans: normal levels from infancy to adulthood. J. Clin. Endocrinol. Metab. 81, 571-576 (1996). (Pubitemid 26055665)
70. van Rooij, I. A. et al. Anti-müllerian hormone is a promising predictor for the occurrence of the menopausal transition. Menopause 11, 601-606 (2004). (Pubitemid 40353222)
71. van Rooij, I. A. et al. Serum antimullerian hormone levels best reflect the reproductive decline with age in normal women with proven fertility: A longitudinal study. Fertil. Steril. 83, 979-987 (2005).
72. de Vet, A., Laven, J. S., de Jong, F. H., Themmen, A. P. N. & Fauser, B. C. Antimüllerian hormone serum levels: a putative marker for ovarian aging. Fertil. Steril. 77, 357-362 (2002). (Pubitemid 34083560)
73. Fanchin, R. et al. Serum anti-Müllerian hormone is more strongly related to ovarian follicular status than serum inhibin B, estradiol, FSH and LH on day 3. Hum. Reprod. 18, 323-327 (2003). (Pubitemid 36236265)
74. van Rooij, I. A. et al. Serum anti-Müllerian hormone levels: a novel measure of ovarian reserve. Hum. Reprod. 17, 3065-3071 (2002). (Pubitemid 35469254)
75. Hansen, K. R., Hodnett, G. M., Knowlton, N. & Craig, L. B. Correlation of ovarian reserve tests with histologically determined primordial follicle number. Fertil. Steril. 95, 170-175 (2011).
76. Kevenaar, M. E. et al. Serum anti-mullerian hormone levels reflect the size of the primordial follicle pool in mice. Endocrinology 147, 3228-3234 (2006). (Pubitemid 43901114)
77. Seifer, D. B., Baker, V. L. & Leader, B. Age-specific serum anti-Müllerian hormone values for 17,120 women presenting to fertility centers within the United States. Fertil. Steril. 95, 747-750 (2011).
78. Kelsey, T. W., Wright, P., Nelson, S. M., Anderson, R. A. & Wallace, W. H. A validated model of serum anti-müllerian hormone from conception to menopause. PLoS ONE 6, e22024 (2011).
79. Nelson, S. M. et al. External validation of nomogram for the decline in serum anti-Müllerian hormone in women: a population study of 15,834 infertility patients. Reprod. Biomed. Online 23, 204-206 (2011).
80. Hehenkamp, W. J. et al. Anti-Müllerian hormone levels in the spontaneous menstrual cycle do not show substantial fluctuation. J. Clin. Endocrinol. Metab. 91, 4057-4063 (2006). (Pubitemid 44536885)
81. La Marca, A., Stabile, G., Artenisio, A. C. & Volpe, A. Serum anti-Müllerian hormone throughout the human menstrual cycle. Hum. Reprod. 21, 3103-3107 (2006). (Pubitemid 44811610)
82. Streuli, I. et al. Serum antimüllerian hormone levels remain stable throughout the menstrual cycle and after oral or vaginal administration of synthetic sex steroids. Fertil. Steril. 90, 395-400 (2008).
83. Tsepelidis, S. et al. Stable serum levels of anti-Müllerian hormone during the menstrual cycle: a prospective study in normo-ovulatory women. Hum. Reprod. 22, 1837-1840 (2007). (Pubitemid 47062749)
84. Robertson, D. M., Hale, G. E., Fraser, I. S., Hughes, C. L. & Burger, H. G. Changes in serum antimüllerian hormone levels across the ovulatory menstrual cycle in late reproductive age. Menopause 18, 521-524 (2011).
85. Sowers, M. et al. Anti-Müllerian hormone and inhibin B variability during normal menstrual cycles. Fertil. Steril. 94, 1482-1486 (2010).
86. Streuli, I. et al. Clinical uses of anti-Müllerian hormone assays: pitfalls and promises. Fertil. Steril. 91, 226-230 (2009).
87. Wunder, D. M., Bersinger, N. A., Yared, M., Kretschmer, R. & Birkhäuser, M. H. Statistically significant changes of antimüllerian hormone and inhibin levels during the physiologic menstrual cycle in reproductive age women. Fertil. Steril. 89, 927-933 (2008). (Pubitemid 351491234)
88. Fanchin, R. et al. High reproducibility of serum anti-Mullerian hormone measurements suggests a multi-staged follicular secretion and strengthens its role in the assessment of ovarian follicular status. Hum. Reprod. 20, 923-927 (2005). (Pubitemid 40667836)
89. Sowers, M. R. et al. Anti-mullerian hormone and inhibin B in the definition of ovarian aging and the menopause transition. J. Clin. Endocrinol. Metab. 93, 3478-3483 (2008).
90. van Disseldorp, J. et al. Relationship of serum antimüllerian hormone concentration to age at menopause. J. Clin. Endocrinol. Metab. 93, 2129-2134 (2008). (Pubitemid 351831526)
91. Broer, S. L. et al. Anti-mullerian hormone predicts menopause: a long-term follow-up study in normoovulatory women. J. Clin. Endocrinol. Metab. 96, 2532-2539 (2011).
92. Tehrani, F. R., Shakeri, N., Solaymani-Dodaran, M. & Azizi, F. Predicting age at menopause from serum antimüllerian hormone concentration. Menopause 18, 766-770 (2011).
93. Tehrani, F. R., Solaymani-Dodaran, M. & Azizi, F. A single test of antimullerian hormone in late reproductive-aged women is a good predictor of menopause. Menopause 16, 797-802 (2009).
94. Hendriks, D. J., Mol, B. W., Bancsi, L. F., Te Velde, E. R. & Broekmans, F. J. Antral follicle count in the prediction of poor ovarian response and pregnancy after in vitro fertilization: a meta-analysis and comparison with basal follicle-stimulating hormone level. Fertil. Steril. 83, 291-301 (2005). (Pubitemid 40221779)
95. Seifer, D. B., MacLaughlin, D. T., Christian, B. P., Feng, B. & Shelden, R. M. Early follicular serum müllerian-inhibiting substance levels are associated with ovarian response during assisted reproductive technology cycles. Fertil. Steril. 77, 468-471 (2002). (Pubitemid 34177199)
96. La Marca, A. et al. Anti-Müllerian hormone measurement on any day of the menstrual cycle strongly predicts ovarian response in assisted reproductive technology. Hum. Reprod. 22, 766-771 (2007).
97. Nelson, S. M., Yates, R. W. & Fleming, R. Serum anti-Müllerian hormone and FSH: prediction of live birth and extremes of response in stimulated cycles-implications for individualization of therapy. Hum. Reprod. 22, 2414-2421 (2007). (Pubitemid 47289055)
98. Nelson, S. M. et al. Anti-Müllerian hormone-based approach to controlled ovarian stimulation for assisted conception. Hum. Reprod. 24, 867-875 (2009).
99. Broer, S. L. et al. AMH and AFC as predictors of excessive response in controlled ovarian hyperstimulation: a meta-analysis. Hum. Reprod. Update 17, 46-54 (2011).
100. Broer, S. L., Mol, B., Dolleman, M., Fauser, B. C. & Broekmans, F. J. The role of anti-Müllerian hormone assessment in assisted reproductive technology outcome. Curr. Opin. Obstet. Gynecol. 22, 193-201 (2010).
101. Broer, S. L., Mol, B. W., Hendriks, D. & Broekmans, F. J. The role of antimüllerian hormone in prediction of outcome after IVF: comparison with the antral follicle count. Fertil. Steril. 91, 705-714 (2009).
102. Fadini, R. et al. Anti-mullerian hormone as a predictive marker for the selection of women for oocyte in vitro maturation treatment. J. Assist. Reprod. Genet. 28, 501-508 (2011).
103. Gnoth, C. et al. Relevance of anti-Müllerian hormone measurement in a routine IVF program. Hum. Reprod. 23, 1359-1365 (2008). (Pubitemid 351770586)
104. Lie Fong, S. et al. Anti-Müllerian hormone: a marker for oocyte quantity, oocyte quality and embryo quality? Reprod. Biomed. Online 16, 664-670 (2008).
105. Smeenk, J. M. et al. Antimüllerian hormone predicts ovarian responsiveness, but not embryo quality or pregnancy, after in vitro fertilization or intracyoplasmic sperm injection. Fertil. Steril. 87, 223-226 (2007). (Pubitemid 46013883)
106. La Marca, A. et al. Serum anti-müllerian hormone levels in women with secondary amenorrhea. Fertil. Steril. 85, 1547-1549 (2006).
107. Méduri, G. et al. Serum anti-Müllerian hormone expression in women with premature ovarian failure. Hum. Reprod. 22, 117-123 (2007). (Pubitemid 44942674)
108. Bachelot, A. et al. Phenotyping and genetic studies of 357 consecutive patients presenting with premature ovarian failure. Eur. J. Endocrinol. 161, 179-187 (2009).
109. Knauff, E. A. et al. Anti-Müllerian hormone, inhibin B, and antral follicle count in young women with ovarian failure. J. Clin. Endocrinol. Metab. 94, 786-792 (2009).
110. Sullivan, A. K. et al. Association of FMR1 repeat size with ovarian dysfunction. Hum. Reprod. 20, 402-412 (2005). (Pubitemid 40277608)
111. Rohr, J. et al. Anti-Mullerian hormone indicates early ovarian decline in fragile X mental retardation (FMR1) premutation carriers: a preliminary study. Hum. Reprod. 23, 1220-1225 (2008). (Pubitemid 351757318)
112. Spath, M. A. et al. Intra-individual stability over time of standardized anti-Müllerian hormone in FMR1 premutation carriers. Hum. Reprod. 26, 2185-2191 (2011).
113. Gleicher, N., Weghofer, A., Oktay, K. & Barad, D. H. Correlation of triple repeats on the FMR1 (fragile X) gene to ovarian reserve: a new infertility test? Acta Obstet. Gynecol. Scand. 88, 1024-1030 (2009).
114. Gleicher, N., Weghofer, A., Oktay, K. & Barad, D. Relevance of triple CGG repeats in the FMR1 gene to ovarian reserve. Reprod. Biomed. Online 19, 385-390 (2009).
115. Gleicher, N., Weghofer, A. & Barad, D. H. A pilot study of premature ovarian senescence: I. Correlation of triple CGG repeats on the FMR1 gene to ovarian reserve parameters FSH and anti-Müllerian hormone. Fertil. Steril. 91, 1700-1706 (2009).
116. Bennett, C. E., Conway, G. S., Macpherson, J. N., Jacobs, P. A. & Murray, A. Intermediate sized CGG repeats are not a common cause of idiopathic premature ovarian failure. Hum. Reprod. 25, 1335-1338 (2010).
117. Abir, R. et al. Turner's syndrome and fertility: current status and possible putative prospects. Hum. Reprod. Update 7, 603-610 (2001). (Pubitemid 33069619)
118. Toniolo, D. & Rizzolio, F. X chromosome and ovarian failure. Semin. Reprod. Med. 25, 264-271 (2007). (Pubitemid 47047910)
119. Borgström, B. et al. Fertility preservation in girls with turner syndrome: prognostic signs of the presence of ovarian follicles. J. Clin. Endocrinol. Metab. 94, 74-80 (2009).
120. Purushothaman, R., Lazareva, O., Oktay, K. & Ten, S. Markers of ovarian reserve in young girls with Turner's syndrome. Fertil. Steril. 94, 1557-1559 (2010).
121. Tsigkou, A. et al. High serum inhibin concentration discriminates autoimmune oophoritis from other forms of primary ovarian insufficiency. J. Clin. Endocrinol. Metab. 93, 1263-1269 (2008). (Pubitemid 351519719)
122. La Marca, A. et al. Primary ovarian insufficiency due to steroidogenic cell autoimmunity is associated with a preserved pool of functioning follicles. J. Clin. Endocrinol. Metab. 94, 3816-3823 (2009).
123. Gleicher, N., Weghofer, A. & Barad, D. H. A pilot study of premature ovarian senescence: II. Different genotype and phenotype for genetic and autoimmune etiologies. Fertil. Steril. 91, 1707-1711 (2009).
124. Clowse, M. E. et al. Ovarian preservation by GnRH agonists during chemotherapy: a meta-analysis. J. Womens Health 18, 311-319 (2009).
125. Nitzschke, M. et al. GnRH analogs do not protect ovaries from chemotherapy-induced ultrastructural injury in Hodgkin's lymphoma patients. Arch. Gynecol. Obstet. 282, 83-88 (2010).
126. Sánchez-Serrano, M. et al. Twins born after transplantation of ovarian cortical tissue and oocyte vitrification. Fertil. Steril. 93, 268.e11-268.e13 (2010).
127. Meirow, D. et al. Monitoring the ovaries after autotransplantation of cryopreserved ovarian tissue: endocrine studies, in vitro fertilization cycles, and live birth. Fertil. Steril. 87, 418.e7-418.e15 (2007).
128. Janse, F. et al. Limited value of ovarian function markers following orthotopic transplantation of ovarian tissue after gonadotoxic treatment. J. Clin. Endocrinol. Metab. 96, 1136-1144 (2011).
129. Schmidt, K. T. et al. Autotransplantation of cryopreserved ovarian tissue in 12 women with chemotherapy-induced premature ovarian failure: the Danish experience. Fertil. Steril. 95, 695-701 (2011).
130. Lie Fong, S. et al. Assessment of ovarian reserve in adult childhood cancer survivors using anti-Müllerian hormone. Hum. Reprod. 24, 982-990 (2009).
131. Rosendahl, M. et al. Ovarian function after removal of an entire ovary for cryopreservation of pieces of cortex prior to gonadotoxic treatment: a follow-up study. Hum. Reprod. 23, 2475-2483 (2008).
132. van Beek, R. D. et al. Anti-Mullerian hormone is a sensitive serum marker for gonadal function in women treated for Hodgkin's lymphoma during childhood. J. Clin. Endocrinol. Metab. 92, 3869-3874 (2007). (Pubitemid 47607635)
133. Bath, L. E., Wallace, W. H., Shaw, M. P., Fitzpatrick, C. & Anderson, R. A. Depletion of ovarian reserve in young women after treatment for cancer in childhood: detection by anti-Müllerian hormone, inhibin B and ovarian ultrasound. Hum. Reprod. 18, 2368-2374 (2003). (Pubitemid 37427819)
134. Lie Fong, S. et al. Anti-müllerian hormone as a marker of ovarian function in women after chemotherapy and radiotherapy for haematological malignancies. Hum. Reprod. 23, 674-678 (2008). (Pubitemid 351651205)
135. Su, H. I. et al. Antimullerian hormone and inhibin B are hormone measures of ovarian function in late reproductive-aged breast cancer survivors. Cancer 116, 592-599 (2010).
136. Partridge, A. H. et al. Ovarian reserve in women who remain premenopausal after chemotherapy for early stage breast cancer. Fertil. Steril. 94, 638-644 (2010).
137. Lutchman Singh, K. et al. Predictors of ovarian reserve in young women with breast cancer. Br. J. Cancer 96, 1808-1816 (2007). (Pubitemid 46912025)
138. Anderson, R. A., Themmen, A. P., Al-Qahtani, A., Groome, N. P. & Cameron, D. A. The effects of chemotherapy and long-term gonadotrophin suppression on the ovarian reserve in premenopausal women with breast cancer. Hum. Reprod. 21, 2583-2592 (2006). (Pubitemid 44542149)
139. Yu, B. et al. Changes in markers of ovarian reserve and endocrine function in young women with breast cancer undergoing adjuvant chemotherapy. Cancer 116, 2099-2105 (2010).
140. Rosendahl, M. et al. Dynamics and mechanisms of chemotherapy-induced ovarian follicular depletion in women of fertile age. Fertil. Steril. 94, 156-166 (2010).
141. Anders, C. et al. A pilot study of predictive markers of chemotherapy-related amenorrhea among premenopausal women with early stage breast cancer. Cancer Invest. 26, 286-295 (2008). (Pubitemid 351329008)
142. Anderson, R. A. & Cameron, D. A. Pretreatment serum anti-müllerian hormone predicts long-term ovarian function and bone mass after chemotherapy for early breast cancer. J. Clin. Endocrinol. Metab. 96, 1336-1343 (2011).
143. Kaipia, A. & Hsueh, A. J. Regulation of ovarian follicle atresia. Annu. Rev. Physiol. 59, 349-363 (1997). (Pubitemid 27142446)
144. Massagué, J. TGF-β signal transduction. Annu. Rev. Biochem. 67, 753-791 (1998).
145. Massagué, J. & Wotton, D. Transcriptional control by the TGF-beta/Smad signaling system. Embo. J. 19, 1745-1754 (2000). (Pubitemid 30204386)
146. Visser, J. A. AMH signaling: from receptor to target gene. Mol. Cell. Endocrinol. 211, 65-73 (2003). (Pubitemid 37491237)
147. Erickson, G. F. & Shimasaki, S. The spatiotemporal expression pattern of the bone morphogenetic protein family in rat ovary cell types during the estrous cycle. Reprod. Biol. Endocrinol. 1, 9 (2003).